Please login to the form below

Not currently logged in
Email:
Password:

ELND005

This page shows the latest ELND005 news and features for those working in and with pharma, biotech and healthcare.

Transition takes on Lilly muscle-boosting drug

Transition takes on Lilly muscle-boosting drug

Meanwhile, the Canadian company also has an in-house candidate - ELND005 - for the treatment of agitation and aggression in Alzheimer's disease as well as neuropsychiatric symptoms in Down's syndrome

Latest news

  • FDA fast-tracks Elan’s Alzheimer’s drug FDA fast-tracks Elan’s Alzheimer’s drug

    Elan's limited pipeline received a boost yesterday with the decision by the US Food and Drug Administration (FDA) to grant fast-track status to its Alzheimer's disease candidate ELND005. ... The designation is reserved for drugs that address unmet

  • Royalty Pharma raises Elan bid as deals keep coming Royalty Pharma raises Elan bid as deals keep coming

    Finally, Speranza is a new company set up in Ireland to handle the development of ELND005 (scyllo-inositol), a clinical-stage drug candidate with potential in bipolar disease, agitation and aggression

  • Lifting the fog

    Other late-stage failures. Another drug that is close to treading the same path as semagacestat is ELND005 (Elan). ... In a phase II trial, low-dose ELND005 failed to outperform placebo in primary cognitive and functional endpoints.

  • Lilly halts Alzheimer's drug development

    Topline summary results of a phase II study for that drug, known as ELND005, showed that it did not achieve significance on cognitive and functional primary outcome measures.

  • FDA approves generic Aricept for dementia

    No direct relationships between the deaths of the patients and the experimental ELND005 compound have been made. ... ELND005 has received fast track designation from the US FDA for treatment of mild to moderate Alzheimer's disease.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2013 Pharma deals during June 2013

    elected not to close the various deals on offer as noted in aie the Theravance, AOP Orphan and the Speranza ELND005 transactions.

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    Elan/ Speranza. Product spin out. Product spin out ELND005 phase 2 CNS drug.

  • Pharma deals during May 2013 Pharma deals during May 2013

    asset ELND005 to a new company, Speranza, whereby Elan pays Speranza (not the other way around) up to $70m in fees and loans. ... senior management who work on ELND005 and who will transfer from Elan to Speranza.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....